Medtronic
 
 

Activa® Therapy

Activa Tremor Control Therapy — U.S. Clinical Study



Morrie was diagnosed with essential tremor in 1982, at age 58. He began using Activa® Tremor Control Therapy in 1996 to manage his disabling tremor. Patient results vary. Not all patients respond in the same way.

Study Results1
A modified Mini Mental Status Examination completed by patients in the study showed no cognitive effects related to Activa Tremor Control Therapy.

Activities of daily living (ADL) showed statistically significant improvement in seven scales for essential tremor patients. In patients with Parkinsonian tremor, ADL scores showed a trend in improvement in four scales, but only the tremor-specific ADL showed statistically significant improvement.

Patients’ subjective evaluation of their disability was improved in both groups when compared to a pre-implant assessment. During the clinical trial, 17 Parkinsonian tremor patients increased use and eight decreased use of levodopa. Six patients decreased use of anticholinergics.

References
  1. Medtronic Activa Therapy Clinical Summary 2002, UC19990178 EN.

Additional Information

  • Results
  • Study Design
  • Register for updates on Medtronic Activa Therapy
  • Visit WeMove.org to learn more about movement disorders education and treatment information
  • Contact Medtronic Activa Physician Services